Xenothera

Xenothera’s clinical research includes relapsed/refractory peripheral T-cell lymphoma, with interest in treatments directed at malignant T-cell populations and disease control in aggressive hematologic cancer.

• Relapsed/refractory PTCL
• Anti-tumor activity in T-cell malignancy
• Safety and tolerability in hematologic oncology

The sponsor’s work in this area is centered on lymphoma therapy and the clinical assessment of novel antibody-based approaches for T-cell cancers.